You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動丨新冠感染率激增!新冠特效藥概念股集體走強,以嶺藥業等多股升停
格隆匯 08-12 10:32
A股市場新冠特效藥概念股集體走強,其中,廣生堂20CM升停,舒泰神升超15%,紅日藥業升超13%,以嶺藥業、新華製藥10CM升停,眾生藥業逼近升停,仟源醫藥升超8%,雅本化學、拓新藥業升超7%,上海凱寶升近7%,翰宇藥業升近6%。消息面上,世界衞生組織日前警吿,新冠病毒感染率正在全球範圍內激增,而且這種情況不太可能很快得到改善,國際社會應關注夏季新冠感染異常增多情況。世衞組織表示,來自84個國家的哨點監測系統的數據顯示,新冠病毒檢測呈陽性的百分比在過去幾周裏一直在上升。目前,全球範圍內新冠陽性檢出率略超10%,歐洲陽性率超過20%。世衞組織還擔心,更嚴重的新冠病毒變種可能很快就會出現,建議為最高危人羣接種新冠疫苗。中國疾控中心8月8日發佈2024年7月全國新型冠狀病毒感染疫情情況,夏季流感等病毒感染佔比下降,新型冠狀病毒感染人數有上升,佔比升高。數據顯示,全國範圍內流感樣病例新冠病毒陽性率有所上升,從7月1日-7月7日的8.9%持續上升至7月22日-7月28日的18.7%,主要流行株均為奧密克戎變異株,我國主要以JN.1系列變異株和XDV系列變異株為主。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account